These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 26888161)

  • 1. Prediction of clinical and endoscopic responses to anti-tumor necrosis factor-α antibodies in ulcerative colitis.
    Morita Y; Bamba S; Takahashi K; Imaeda H; Nishida A; Inatomi O; Sasaki M; Tsujikawa T; Sugimoto M; Andoh A
    Scand J Gastroenterol; 2016 Aug; 51(8):934-41. PubMed ID: 26888161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
    Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
    Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and laboratory markers associated with anti-TNF-alpha trough levels and anti-drug antibodies in patients with inflammatory bowel diseases.
    Grinman AB; de Souza MDGC; Bouskela E; Carvalho ATP; de Souza HSP
    Medicine (Baltimore); 2020 Mar; 99(10):e19359. PubMed ID: 32150077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-Year Clinical Outcomes in an IBD Cohort Who Have Previously Had Anti-TNFa Trough and Antibody Levels Assessed.
    Tighe D; Hall B; Jeyarajah SK; Smith S; Breslin N; Ryan B; McNamara D
    Inflamm Bowel Dis; 2017 Jul; 23(7):1154-1159. PubMed ID: 28486256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ulcerative colitis endoscopic index of severity is associated with long-term prognosis in ulcerative colitis patients treated with infliximab.
    Saigusa K; Matsuoka K; Sugimoto S; Arai M; Kiyohara H; Takeshita K; Mizuno S; Mori K; Nanki K; Takeshita T; Nakazato Y; Yajima T; Naganuma M; Hisamatsu T; Ogata H; Iwao Y; Kanai T
    Dig Endosc; 2016 Sep; 28(6):665-70. PubMed ID: 26997640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Normalization of mucosal tumor necrosis factor-α: A new criterion for discontinuing infliximab therapy in ulcerative colitis.
    Olsen T; Rismo R; Gundersen MD; Paulssen EJ; Johnsen K; Kvamme JM; Goll R; Florholmen J
    Cytokine; 2016 Mar; 79():90-5. PubMed ID: 26775117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
    Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
    J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.
    Roblin X; Marotte H; Rinaudo M; Del Tedesco E; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
    Clin Gastroenterol Hepatol; 2014 Jan; 12(1):80-84.e2. PubMed ID: 23891927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of psoriasis in IBD patients under TNF-antagonist therapy is associated neither with anti-TNF-antagonist antibodies nor trough levels.
    Protic M; Schoepfer A; Yawalkar N; Vavricka S; Seibold F
    Scand J Gastroenterol; 2016 Dec; 51(12):1482-1488. PubMed ID: 27534974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of tissue healing in ulcerative colitis patients treated with anti-TNF.
    Viazis N; Giakoumis M; Bamias G; Goukos D; Koukouratos T; Katopodi K; Karatzas P; Triantos C; Tsolias C; Theocharis G; Daikos GL; Ladas SD; Karamanolis DG; Mantzaris GJ
    Dig Liver Dis; 2017 Jan; 49(1):29-33. PubMed ID: 27866814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Golimumab for moderately to severely active ulcerative colitis.
    Kedia S; Ahuja V; Makharia GK
    Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab therapy downregulation of basic fibroblast growth factor/syndecan 1 link: a possible molecular pathway of mucosal healing in ulcerative colitis.
    Ierardi E; Giorgio F; Zotti M; Rosania R; Principi M; Marangi S; Della Valle N; De Francesco V; Di Leo A; Ingrosso M; Panella C
    J Clin Pathol; 2011 Nov; 64(11):968-72. PubMed ID: 21945924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis.
    Olsen T; Goll R; Cui G; Christiansen I; Florholmen J
    Cytokine; 2009 May; 46(2):222-7. PubMed ID: 19286392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Ulcerative Colitis Response Index for Detection of Mucosal Healing in Patients Treated With Anti-tumour Necrosis Factor.
    de Bruyn M; Ringold R; Martens E; Ferrante M; Van Assche G; Opdenakker G; Dukler A; Vermeire S
    J Crohns Colitis; 2020 Feb; 14(2):176-184. PubMed ID: 31628842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-Life Comparison of Different Anti-TNF Biologic Therapies for Ulcerative Colitis Treatment: A Retrospective Cohort Study.
    Barberio B; Zingone F; Frazzoni L; D'Incà R; Maccarone MC; Ghisa M; Massimi D; Lorenzon G; Savarino EV
    Dig Dis; 2021; 39(1):16-24. PubMed ID: 32450562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.
    Ungar B; Levy I; Yavne Y; Yavzori M; Picard O; Fudim E; Loebstein R; Chowers Y; Eliakim R; Kopylov U; Ben-Horin S
    Clin Gastroenterol Hepatol; 2016 Apr; 14(4):550-557.e2. PubMed ID: 26538204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reliability and initial validation of the ulcerative colitis endoscopic index of severity.
    Travis SP; Schnell D; Krzeski P; Abreu MT; Altman DG; Colombel JF; Feagan BG; Hanauer SB; Lichtenstein GR; Marteau PR; Reinisch W; Sands BE; Yacyshyn BR; Schnell P; Bernhardt CA; Mary JY; Sandborn WJ
    Gastroenterology; 2013 Nov; 145(5):987-95. PubMed ID: 23891974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Ulcerative Colitis Endoscopic Index of Severity More Accurately Reflects Clinical Outcomes and Long-term Prognosis than the Mayo Endoscopic Score.
    Ikeya K; Hanai H; Sugimoto K; Osawa S; Kawasaki S; Iida T; Maruyama Y; Watanabe F
    J Crohns Colitis; 2016 Mar; 10(3):286-95. PubMed ID: 26581895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients.
    Iborra M; Pérez-Gisbert J; Bosca-Watts MM; López-García A; García-Sánchez V; López-Sanromán A; Hinojosa E; Márquez L; García-López S; Chaparro M; Aceituno M; Calafat M; Guardiola J; Belloc B; Ber Y; Bujanda L; Beltrán B; Rodríguez-Gutiérrez C; Barrio J; Cabriada JL; Rivero M; Camargo R; van Domselaar M; Villoria A; Schuterman HS; Hervás D; Nos P;
    J Gastroenterol; 2017 Jul; 52(7):788-799. PubMed ID: 27722996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.